image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.98
-9.26 %
$ 38.8 M
Market Cap
-0.74
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TELA stock under the worst case scenario is HIDDEN Compared to the current market price of 0.98 USD, TELA Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TELA stock under the base case scenario is HIDDEN Compared to the current market price of 0.98 USD, TELA Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TELA stock under the best case scenario is HIDDEN Compared to the current market price of 0.98 USD, TELA Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TELA

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
69.3 M REVENUE
18.56%
-34.1 M OPERATING INCOME
22.60%
-37.8 M NET INCOME
18.91%
-41.6 M OPERATING CASH FLOW
-1.81%
4.45 M INVESTING CASH FLOW
843.07%
43.1 M FINANCING CASH FLOW
-6.94%
17.6 M REVENUE
-6.90%
-8.35 M OPERATING INCOME
10.80%
-9.21 M NET INCOME
11.22%
-7.53 M OPERATING CASH FLOW
16.16%
-190 K INVESTING CASH FLOW
-55.74%
42.9 M FINANCING CASH FLOW
43683.67%
Balance Sheet TELA Bio, Inc.
image
Current Assets 78.1 M
Cash & Short-Term Investments 52.7 M
Receivables 10.1 M
Other Current Assets 15.3 M
Non-Current Assets 8.5 M
Long-Term Investments 0
PP&E 4.08 M
Other Non-Current Assets 4.42 M
60.84 %11.66 %17.68 %4.71 %5.11 %Total Assets$86.6m
Current Liabilities 15.6 M
Accounts Payable 2.15 M
Short-Term Debt 0
Other Current Liabilities 13.5 M
Non-Current Liabilities 42.5 M
Long-Term Debt 41.1 M
Other Non-Current Liabilities 1.39 M
3.69 %23.15 %70.77 %Total Liabilities$58.1m
EFFICIENCY
Earnings Waterfall TELA Bio, Inc.
image
Revenue 69.3 M
Cost Of Revenue 22.8 M
Gross Profit 46.5 M
Operating Expenses 80.6 M
Operating Income -34.1 M
Other Expenses 3.73 M
Net Income -37.8 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)69m(23m)46m(81m)(34m)(4m)(38m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
67.08% GROSS MARGIN
67.08%
-49.23% OPERATING MARGIN
-49.23%
-54.60% NET MARGIN
-54.60%
-132.97% ROE
-132.97%
-43.71% ROA
-43.71%
-47.89% ROIC
-47.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TELA Bio, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -37.8 M
Depreciation & Amortization 1.01 M
Capital Expenditures -989 K
Stock-Based Compensation 4.36 M
Change in Working Capital 0
Others -9.55 M
Free Cash Flow -42.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TELA Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for TELA of $10 , with forecasts ranging from a low of $8 to a high of $14 .
TELA Lowest Price Target Wall Street Target
8 USD 716.33%
TELA Average Price Target Wall Street Target
10 USD 920.41%
TELA Highest Price Target Wall Street Target
14 USD 1328.57%
Price
Max Price Target
Min Price Target
Average Price Target
1414121210108866442200May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership TELA Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
2.02 M USD 1
Bought
0 USD 0
0-3 MONTHS
410 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Greg Chodaczek - The Gilmartin Group Antony Koblish - Co-founder, President and Chief Executive Office Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens Matt O'Brien - Piper Sandler Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.53 per share a year ago. zacks.com - 1 month ago
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com - 1 month ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 2 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 4 months ago
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference. globenewswire.com - 5 months ago
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 months ago
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago. zacks.com - 5 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 5 months ago
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the closing of its previously announced underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, for gross proceeds of $46 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. All shares of common stock and pre-funded warrants were sold by TELA. globenewswire.com - 5 months ago
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, collectively, for gross proceeds of $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. In addition, TELA has granted the underwriters a 30-day option to purchase up to an additional 2,670,000 shares of its common stock at the public offering price for the common stock, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants are being offered by TELA. The offering is expected to close on or about October 24, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 5 months ago
8. Profile Summary

TELA Bio, Inc. TELA

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 38.8 M
Dividend Yield 0.00%
Description TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Contact 1 Great Valley Parkway, Malvern, PA, 19355 https://www.telabio.com
IPO Date Nov. 8, 2019
Employees 209
Officers Mr. Gregory A. Firestone Chief Commercial Officer Mr. D. Taylor Ocasio General Counsel & Corporate Secretary Mr. Antony Koblish Co-founder, President, Chief Executive Officer & Director Ms. Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Mr. Paul Talmo Chief Technology Officer Mr. Peter C. Murphy Chief Commercial Officer Ms. Jennifer Lou Armstrong Senior Vice President of Human Resources Louisa Smith Investor Relations Contact Officer Mr. Roberto E. Cuca J.D. Chief Financial Officer & Chief Operating Officer Mr. Michael Leonard Senior Vice President of Technical Operations